Issues
-
Cover Image
Cover Image
Under proliferative conditions in vitro, epidermal growth factor receptor (EGFR)–positive cancer stem cell (CSC) cultures transduced with small hairpin RNA (shRNA) against EGFR displayed dramatic morphologic changes, with neurospheres becoming highly adhesive and cells appearing well differentiated (right). Consistently, the frequency of glial fibrillary acidic protein–positive astrocyte-like cells in shRNA-transduced CSCs was significantly increased as compared to that of controls (left). Tuj1, red; GFAP, green; merge, yellow; TOPRO-3, dark blue. Magnifications: top, 200x; bottom, 400x. For details see the article by Mazzoleni and colleagues on page 7500 of this issue. - PDF Icon PDF LinkTable of Contents
Cancer Research
Table of Contents
Breaking Advances
Reviews
Meeting Reports
Clinical Studies
MLH1 Founder Mutations with Moderate Penetrance in Spanish Lynch Syndrome Families
Clinical Pharmacology of Resveratrol and Its Metabolites in Colorectal Cancer Patients
Integrated Systems and Technologies
Hyperpolarized 13C Spectroscopic Imaging Informs on Hypoxia-Inducible Factor-1 and Myc Activity Downstream of Platelet-Derived Growth Factor Receptor
Microenvironment and Immunology
Antibody-Dependent Natural Killer Cell–Mediated Cytotoxicity Engendered by a Kinase-Inactive Human HER2 Adenovirus-Based Vaccination Mediates Resistance to Breast Tumors
A Galectin-3 Ligand Corrects the Impaired Function of Human CD4 and CD8 Tumor-Infiltrating Lymphocytes and Favors Tumor Rejection in Mice
Molecular and Cellular Pathobiology
Epidermal Growth Factor Receptor Expression Identifies Functionally and Molecularly Distinct Tumor-Initiating Cells in Human Glioblastoma Multiforme and Is Required for Gliomagenesis
Nongenomic Effects of Cisplatin: Acute Inhibition of Mechanosensitive Transporters and Channels without Actin Remodeling
Interaction with Vascular Endothelium Enhances Survival in Primary Chronic Lymphocytic Leukemia Cells via NF-κB Activation and De novo Gene Transcription
Prevention and Epidemiology
Therapeutics, Targets, and Chemical Biology
Novel Matrix Metalloproteinase Inhibitor [18F]Marimastat-Aryltrifluoroborate as a Probe for In vivo Positron Emission Tomography Imaging in Cancer
Zoledronic Acid as a New Adjuvant Therapeutic Strategy for Ewing's Sarcoma Patients
Liver Cancer Protease Activity Profiles Support Therapeutic Options with Matrix Metalloproteinase–Activatable Oncolytic Measles Virus
GP369, an FGFR2-IIIb–Specific Antibody, Exhibits Potent Antitumor Activity against Human Cancers Driven by Activated FGFR2 Signaling
Tumor and Stem Cell Biology
Cancer-Related Epigenome Changes Associated with Reprogramming to Induced Pluripotent Stem Cells
Activation of Murine Double Minute 2 by Akt in Mammary Epithelium Delays Mammary Involution and Accelerates Mammary Tumorigenesis
Implication of Metastasis Suppressor NM23-H1 in Maintaining Adherens Junctions and Limiting the Invasive Potential of Human Cancer Cells
Corrections
Journal Archive
Cancer Research
(1941-Present; volumes 1-current)Published twice monthly since 1987. From 1941-1986, published monthly.
(ISSN 0008-5472)
The American Journal of Cancer
(1931-1940; volumes 15-40)Published quarterly in 1931, bimonthly in 1932, and monthly from 1933 to 1940. The journal changed title to Cancer Research in 1941.
(ISSN 0099-7374)
The Journal of Cancer Research
(1916-1930); volumes 1-14)Published quarterly from 1916 through 1930 (publication was suspended from November 1922 to March 1924). The journal changed title to The American Journal of Cancer in 1931.
(ISSN 0099-7013)
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.